[HTML][HTML] Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world …
KA Jabal, H Ben-Amram, K Beiruti… - …, 2021 - eurosurveillance.org
KA Jabal, H Ben-Amram, K Beiruti, Y Batheesh, C Sussan, S Zarka, M Edelstein
Eurosurveillance, 2021•eurosurveillance.orgThe BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but
observational data from populations not included in trials are needed. We describe
immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age,
ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex
but decreased with age. Those with prior infection had antibody titres one magnitude order
higher than naïve individuals regardless of the presence of detectable IgG antibodies pre …
observational data from populations not included in trials are needed. We describe
immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age,
ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex
but decreased with age. Those with prior infection had antibody titres one magnitude order
higher than naïve individuals regardless of the presence of detectable IgG antibodies pre …
The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.
eurosurveillance.org